What’s All the Fuss About? Facts and Figures About Bone Marrow Failure and Conditions

作者: Sudipto Mukherjee , Mikkael A. Sekeres

DOI: 10.1007/S11899-012-0134-1

关键词: MedicinePopulationInternal medicineNatural historyEpidemiologyImmunologyIntensive care medicineDiseaseBone marrow failureAplastic anemiaMyelodysplastic syndromesHematology

摘要: The epidemiology of bone marrow failure conditions is not well understood. Although several population-based studies conducted in the last two decades have generated a wealth information, it still very challenging to interpret disease incidence and prevalence, particularly due changes classification, misdiagnosis patients, frequent underreporting use different referent populations calculate rates. Despite these limitations, available epidemiologic data revealed significant ethnic, geographic clinical differences biology that implications for prevention treatment strategies. With advances made targeted therapies facilitated by identification molecular biomarkers increased curative transplantation approach, natural history entities already changing. diseases seems be next frontier as knowledge gained about risk factors pathobiologic correlates could significantly help designing patient-specific with improved outcomes.

参考文章(91)
X Zhang, C Yang, Incidence survey of aplastic anemia in China. Chinese Medical Sciences Journal. ,vol. 6, pp. 203- 207 ,(1991)
A. S. Yong, J. Menon, M. Rahman, A. S. Goh, V. Purushothaman, Epidemiology of aplastic anaemia in the state of Sabah, Malaysia. The Medical journal of Malaysia. ,vol. 53, pp. 59- 62 ,(1998)
Judith P. Kelly, David W. Kaufman, Micha Levy, The Drug Etiology of Agranulocytosis and Aplastic Anemia ,(1991)
Amrita Krishnan, Smita Bhatia, Marilyn L. Slovak, Daniel A. Arber, Joyce C. Niland, Auayporn Nademanee, Henry Fung, Ravi Bhatia, Ashwin Kashyap, Arturo Molina, Margaret R. O'Donnell, Pablo A. Parker, Irena Sniecinski, David S. Snyder, Ricardo Spielberger, Anthony Stein, Stephen J. Forman, Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. ,vol. 95, pp. 1588- 1593 ,(2000) , 10.1182/BLOOD.V95.5.1588.005K38_1588_1593
Jens Pedersen-Bjergaard, Severin Olesen Larsen, Jan Struck, HeineH. Hansen, Lena Specht, Jens Ersbøll, MogensM. Hansen, NisI. Nissen, RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE: Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy The Lancet. ,vol. 330, pp. 83- 88 ,(1987) , 10.1016/S0140-6736(87)92744-9
E. J. Rodger, I. M. Morison, Myelodysplastic syndrome in New Zealand and Australia. Internal Medicine Journal. ,vol. 42, pp. 1235- 1242 ,(2012) , 10.1111/J.1445-5994.2011.02619.X
D L Darrington, J M Vose, J R Anderson, P J Bierman, M R Bishop, W C Chan, M E Morris, E C Reed, W G Sanger, S R Tarantolo, Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology. ,vol. 12, pp. 2527- 2534 ,(1994) , 10.1200/JCO.1994.12.12.2527
Karen J Phekoo, Mike A Richards, Henrik Moller, Steve A Schey, South Thames Haematology Specialist Committee, The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. Haematologica. ,vol. 91, pp. 1400- 1404 ,(2006) , 10.3324/%X